Pankaj Bhargava - Dicerna Pharmaceuticals Chief Medical Officer
Executive
Dr. Pankaj Bhargava, M.D., is Chief Medical Officer of the Company. Dr. Bhargava was Associate Vice President at Sanofi Oncology from February 2011 to March 2014 prior to joining the Company, where he led the global development of aflibercept culminating in successful approvals by the U.S. Food and Drug Administration, European Medicines Agency and several other regulatory authorities worldwide. Dr. Bhargava also served as the Gastrointestinal Oncology Therapeutic Leader, Chairman of Protocol Review Committee, and a member of the Development Leadership Team at Sanofi Oncology Division. Prior to joining Sanofi, Dr. Bhargava was Vice President Clinical Research and Interim Chief Medical Officer at AVEO Pharmaceuticals, Inc. from November 2006 to February 2011, where he led its clinical programs across all indications spanning from Phase 1 to Phase 3 development and was responsible for clinical and regulatory strategy, clinical development, operations, pharmacovigilance and joint development with alliance partners, among other things. Dr. Bhargava currently serves as an Attending Physician at DanaFarber Cancer Institute and parttime faculty member at Harvard Medical School. Dr. Bhargava holds an M.B., B.S. degree from the University of Delhi, India, and is an alumnus of Harvard Business School Executive Education Program since 2014.
| Age | 47 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 617 621-8097 |
| Web | www.dicerna.com |
Dicerna Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (10.43) % which means that it has lost $10.43 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (95.22) %, meaning that it created substantial loss on money invested by shareholders. Dicerna Pharmaceuticals' management efficiency ratios could be used to measure how well Dicerna Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 64.42 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Dicerna Pharmaceuticals has a current ratio of 2.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dicerna Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Dicerna Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dicerna Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dicerna to invest in growth at high rates of return. When we think about Dicerna Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Trent Musso | Summit Materials | N/A | |
| Jeremy King | 54 | ||
| Gretchen Zech | Arrow Electronics | 54 | |
| Jason Weidman | ScanSource | N/A | |
| Christine Marshall | US Silica Holdings | 55 | |
| Derek Ussery | US Silica Holdings | 39 | |
| Anthony Bencivenga | Arrow Electronics | N/A | |
| Jason Kilgore | Summit Materials | 49 | |
| Julio DaSilva | Summit Materials | N/A | |
| Julia Donnelly | 41 | ||
| Alexandre Conde | ScanSource | N/A | |
| Doniel Sutton | 50 | ||
| John Hourigan | Arrow Electronics | N/A | |
| Tse Yang | 47 | ||
| Ida Ashley | US Silica Holdings | N/A | |
| Charles DePriest | Summit Materials | 51 | |
| Frank Blackwell | ScanSource | N/A | |
| Malik Ducard | 51 | ||
| Steve Kerdock | Arrow Electronics | N/A | |
| Arjun Sreekumar | US Silica Holdings | N/A | |
| Patricia Gil | US Silica Holdings | N/A | |
Management Performance
| Return On Equity | -95.22 | |||
| Return On Asset | -10.43 |
Dicerna Pharmaceuticals Leadership Team
Elected by the shareholders, the Dicerna Pharmaceuticals' board of directors comprises two types of representatives: Dicerna Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dicerna. The board's role is to monitor Dicerna Pharmaceuticals' management team and ensure that shareholders' interests are well served. Dicerna Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dicerna Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bruce Peacock, Independent Director | ||
| Dennis Langer, Independent Director | ||
| David Madden, Independent Chairman of the Board | ||
| Steven Kates, Vice President - Regulatory Affairs | ||
| Douglas Fambrough, President CEO, Director | ||
| Theodore Ashburn, Senior Vice President - Product Strategy & Operations | ||
| Martin Freed, Independent Director | ||
| Kevin Buchi, Independent Director | ||
| Peter Kolchinsky, Independent Director | ||
| Bob Brown, Chief Scientific Officer and Sr. VP | ||
| Brian Halak, Independent Director | ||
| Adam Koppel, Independent Director | ||
| Ralf Rosskamp, Chief Medical Officer | ||
| Rob Ciappenelli, Chief Commercial Officer | ||
| Marc Kozin, Director | ||
| James Weissman, Chief Bus. Officer | ||
| Hardean Achneck, Vice President Head of Medical Development | ||
| John Green, Interim CFO | ||
| Rebecca Peterson, Head of Corporate Communications | ||
| Stephen Hoffman, Independent Director | ||
| Anna Protopapas, Director | ||
| Cynthia Smith, Independent Director | ||
| Robert Ciappenelli, Chief Commercial Officer | ||
| David Caponera, Head of Patient Advocacy and Patient Services | ||
| Regina Paglia, Senior Vice President of Human Resources | ||
| Pankaj Bhargava, Chief Medical Officer |
Dicerna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dicerna Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -95.22 | |||
| Return On Asset | -10.43 | |||
| Profit Margin | (64.53) % | |||
| Operating Margin | (62.88) % | |||
| Current Valuation | 2.48 B | |||
| Shares Outstanding | 77.91 M | |||
| Shares Owned By Insiders | 7.43 % | |||
| Shares Owned By Institutions | 88.54 % | |||
| Number Of Shares Shorted | 4.77 M | |||
| Price To Earning | (1.58) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dicerna Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dicerna Pharmaceuticals' short interest history, or implied volatility extrapolated from Dicerna Pharmaceuticals options trading.
Pair Trading with Dicerna Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dicerna Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dicerna Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Estee Lauder could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Estee Lauder when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Estee Lauder - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Estee Lauder Companies to buy it.
The correlation of Estee Lauder is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Estee Lauder moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Estee Lauder Companies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Estee Lauder can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Dicerna Stock
If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |